Safety and efficacy of resistance training in germ cell cancer patients undergoing chemotherapy: A randomized controlled trial

British Journal of Cancer

Volumn 111, Issue 1, 2014, Pages 8-16

  Christensen, J F ^a   Jones, L W ^b   Tolver, A ^c   Jorgensen L W ^a   Andersen, J L ^d,e   Adamsen, L ^a   Hojman P ^a   Nielsen, R H ^d,e   Rorth M ^a   Daugaard, G ^a  

^a Rigshospitalet   (Denmark)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d BISPEBJERG HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

chemotherapy; germ cell cancer; resistance training; skeletal muscle

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ADULT; ARTICLE; BODY COMPOSITION; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; EXERCISE; GERM CELL TUMOR; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE BIOPSY; MUSCLE DISEASE; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; PATIENT SAFETY; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESISTANCE TRAINING; VASTUS LATERALIS MUSCLE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; HUMANS; MALE; MUSCLE, SKELETAL; NEOPLASMS, GERM CELL AND EMBRYONAL; PROSPECTIVE STUDIES; RESISTANCE TRAINING; SINGLE-BLIND METHOD; TESTICULAR NEOPLASMS;

EID: 84904125406     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.273     Document Type: Article

References (36)

1. Adamsen L, Quist M, Andersen C, Moller T, Herrstedt J, Kronborg D, Baadsgaard MT, Vistisen K, Midtgaard J, Christiansen B, Stage M, Kronborg MT, Rorth M (2009) Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: Randomised controlled trial. BMJ 339: B3410.
2. Andersen JL, Aagaard P (2000) Myosin heavy chain IIX overshoot in human skeletal muscle. Muscle Nerve 23(7): 1095-1104.
3. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE (2010) Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebocontrolled study. J Clin Oncol 28(6): 1054-1060.
4. Atlantis E, Martin SA, Haren MT, Taylor AW, Wittert GA (2009) Inverse associations between muscle mass, strength, and the metabolic syndrome. Metabolism 58(7): 1013-1022.
5. Bergström J (1962) Muscle electrolytes in man. Scand J Clin Lab Invest 68: 1-110.
6. Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Classen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De GU, De SM, De WM, De WR, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germa Jr L, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LH, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De ME, Rick O, Rosti G, Salvioni R, SchraderM, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T,Winter C,Wittekind C (2013)Maintaining success, reducing treatment burden, focusing on survivorship: Highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 24(4): 878-888.
7. Christensen JF, Andersen JL, Adamsen L, Lindegaard B, Mackey AL, Nielsen RH, Rorth M, Daugaard G (2011) Progressive resistance training and cancer testis (PROTRACT)-efficacy of resistance training on muscle function, morphology and inflammatory profile in testicular cancer patients undergoing chemotherapy: Design of a randomized controlled trial. BMC Cancer 11: 326.
8. Christensen JF, Jones LW, Andersen JL, Daugaard G, Rorth M, Hojman P (2014) Muscle dysfunction in cancer patients. Ann Oncol 25(5): 947-958.
9. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, Ladha AB, Proulx C, Vallance JK, Lane K, Yasui Y, McKenzie DC (2007) Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: A multicenter randomized controlled trial. J Clin Oncol 25(28): 4396-4404.
10. Egan B, Zierath JR (2013) Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab 17(2): 162-184.
11. Einhorn LH (1990) Treatment of testicular cancer: A new and improved model. J Clin Oncol 8(11): 1777-1781.
12. Eves ND, Plotnikoff RC (2006) Resistance training and type 2 diabetes: Considerations for implementation at the population level. Diabetes Care 29(8): 1933-1941.
13. Fanzani A, Zanola A, Rovetta F, Rossi S, Aleo MF (2011) Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems. Toxicol Appl Pharmacol 250(3): 312-321.
14. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ (2008) Medical treatment of advanced testicular cancer. JAMA 299(6): 672-684.
15. Fossa SD, Gilbert E, Dores GM, Chen J, McGlynn KA, Schonfeld S, Storm H, Hall P, Holowaty E, Andersen A, Joensuu H, Andersson M, Kaijser M, Gospodarowicz M, Cohen R, Pukkala E, Travis LB (2007) Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99(7): 533-544.
16. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: A randomized controlled trial. J Clin Oncol 28(2): 340-347.
17. Haugnes HS, Wethal T, Aass N, Dahl O, Klepp O, Langberg CW, Wilsgaard T, Bremnes RM, Fossa SD (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 28(30): 4649-4657.
18. HornsbyWE, Douglas PS, West MJ, Kenjale AA, Lane AR, Schwitzer ER, Ray KA, Herndon JE, Coan A, Gutierrez A, Hornsby KP, Hamilton E, Wilke LG, Kimmick GG, Peppercorn JM, Jones LW (2013) Safety and efficacy of aerobic training in operable breast cancer patients receiving neoadjuvant chemotherapy: A phase II randomized trial. Acta Oncol 53: 65-74.
19. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 15(2): 594-603.
20. Janssen I, Heymsfield SB, Wang ZM, Ross R (2000) Skeletal muscle mass and distribution in 468 men and women aged 18-88yr. J Appl Physiol 89(1): 81-88.
21. Koelwyn GJ, Khouri M, Mackey JR, Douglas PS, Jones LW (2012) Running on empty: Cardiovascular reserve capacity and late effects of therapy in cancer survivorship. J Clin Oncol 30(36): 4458-4461.
22. Lukaski HC (1993) Soft tissue composition and bone mineral status: Evaluation by dual-energy X-ray absorptiometry. J Nutr 123(2 Suppl): 438-443.
23. Nyholm B, Qu Z, Kaal A, Pedersen SB, Gravholt CH, Andersen JL, Saltin B, Schmitz O (1997) Evidence of an increased number of type IIb muscle fibers in insulin-resistant first-degree relatives of patients with NIDDM. Diabetes 46(11): 1822-1828.
24. Pletcher MJ, Bibbins-Domingo K, Liu K, Sidney S, Lin F, Vittinghoff E, Hulley SB (2010) Nonoptimal lipids commonly present in young adults and coronary calcium later in life: The CARDIA (Coronary Artery Risk Development in Young Adults) study. Ann Intern Med 153(3): 137-146.
25. Puhan MA, Schunemann HJ, Frey M, Scharplatz M, Bachmann LM (2005) How should COPD patients exercise during respiratory rehabilitation? comparison of exercise modalities and intensities to treat skeletal muscle dysfunction. Thorax 60(5): 367-375.
26. Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1): 9-23.
27. Ruiz JR, Sui X, Lobelo F, Morrow Jr JR, Jackson AW, Sjostrom M, Blair SN (2008) Association between muscular strength and mortality in men: Prospective cohort study. BMJ 337: A439.
28. Sayer AA, Dennison EM, Syddall HE, Gilbody HJ, Phillips DI, Cooper C (2005) Type 2 diabetes, muscle strength, and impaired physical function: The tip of the iceberg? Diabetes Care 28(10): 2541-2542.
29. Sayer AA, Syddall HE, Dennison EM, Martin HJ, Phillips DI, Cooper C, Byrne CD (2007) Grip strength and the metabolic syndrome: Findings from the Hertfordshire Cohort Study. QJM 100(11): 707-713.
30. Schmitz KH, Courneya KS, Matthews C, mark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von G,V, Schwartz AL (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42(7): 1409-1426.
31. Schmitz KH, Holtzman J, Courneya KS, Masse LC, Duval S, Kane R (2005) Controlled physical activity trials in cancer survivors: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 14(7): 1588-1595.
32. Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104(10): 1108-1113.
33. Short KR, Bigelow ML, Nair KS (2009) Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young healthy people. Am J Physiol Endocrinol Metab 297(6): E1260-E1268.
34. Strasser B, Steindorf K, Wiskemann J, Ulrich CM (2013) Impact of resistance training in cancer survivors: A meta-analysis. Med Sci Sports Exerc 45(11): 2080-2090.
35. Ware Jr JE, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6): 473-483.
36. Willemse PP, van der Meer RW, Burggraaf J, van Elderen SG, de Kam ML, de RA, Lamb HJ, Osanto S (2013) Abdominal visceral and subcutaneous fat increase, insulin resistance and hyperlipidemia in testicular cancer patients treated with cisplatin-based chemotherapy. Acta Oncol 53(3): 351-360.